



### **Virtua Cardiology Participates in TAVR, CAD Study**

People who undergo transcatheter aortic valve replacement (TAVR) to treat aortic stenosis often also have coronary artery disease. As a leader in performing heart valve procedures, Virtua Health is participating in a study to determine whether those individuals should undergo a catheter-based intervention with a balloon and stent, or be treated medically.

“It’s not unusual to see concomitant disease in the same patient,” said interventional cardiologist Ibrahim Moussa, DO, FACC, FSCAI, RPVI, principal study investigator at Virtua. “However, there is no agreement on how to best treat these individuals. This study may help determine an optimal path.”

The COMPLETE TAVR study will determine whether a strategy of completed revascularization involving staged percutaneous coronary intervention (PCI) using drug-eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure.

**Study Inclusion:** Men and women with severe symptomatic aortic valve stenosis prior to TAVR

**Exclusion:** PCI already performed within 90 days prior to TAVR or at the same time as the index transfemoral TAVR procedure

The study is sponsored by the University of British Columbia, and is expected to conclude in April 2026. It is being conducted at more than 100 sites across the United States and Canada. Virtua is the only study location in South Jersey.

To refer a patient to the study, contact Danielle Connors at [DConnors@virtua.org](mailto:DConnors@virtua.org).